PositiveSingles.com - the best, most trusted and largest anonymous STD dating site! Herpes Survival Kit - a specially designed pack containing everything you need to combat herpes and cold sore outbreaks (at a minimum cost to your wallet).

only search Racoon.com

"The Good News about the Bad News - 
Herpes: Everything You Need to Know
"  
Terri Warren's new book - which we do endorse.

First time visitor? Please Learn about Registering and read our policy page.
{Home}{Awareness}{Research}{Treatment}{HHP FAQ}{Bookstore}{Bio/Info Page}

The Original Herpes Home Page Discussion Forums

Subject: "Agenus HerpV (aka AG707) completes Ph 2 study enrollment"     Previous Topic | Next Topic
Printer-friendly copy     Email this topic to a friend    
Conferences Herpes News Topic #1584
Reading Topic #1584
muffinadmin
Member since Sep-10-04
6248 posts
Feb-27-13, 05:35 PM (CST)
Click to EMail muffin Click to send private message to muffin Click to view user profileClick to add this user to your buddy list  
"Agenus HerpV (aka AG707) completes Ph 2 study enrollment"
 
http://finance.yahoo.com/news/agenus-herpv-phase-2-study-120302048.html

Agenus' HerpV Phase 2 study to treat genital herpes completes enrollment

Agenus announced it has completed patient screening in its Phase 2 randomized, double-blind, multicenter study for HerpV, a recombinant "off-the-shelf" therapeutic vaccine candidate for the treatment of genital herpes in herpes simplex virus-2, or HSV-2, positive patients. HerpV contains Agenus' QS-21 Stimulon adjuvant.

The Phase 2 study has screened over 100 HSV-2 positive subjects and enrollment has been closed. The study will test the biological efficacy of HerpV as measured by effect on genital viral shedding after three injections of the therapeutic vaccine. A booster injection of HerpV will be given at six months after treatment to evaluate the potential durability of treatment effect.

The HerpV Phase 2 study has been supported by leading clinical experts in the field who have expressed that a reduction in viral shedding could translate into clinical benefit. A therapeutic vaccine to treat HSV-2 infected patients has the potential to provide a major paradigm shift in the treatment of this infection as well as provide significant quality of life benefits.



  Alert | IP Printer-friendly page | Edit | Reply | Reply With Quote | Top

Conferences | Topics | Previous Topic | Next Topic

 

Advertisements appearing on this page do not constitute any endorsement of 
those products or services by HHP or its management.

All opinions expressed here by the HHP, its management and participants constitute just that, opinions.
No medical relationship with any participant is implied in any way.
Each individual's personal doctor is responsible for the medical advice and care of that person.